11/22
07:34 am
abbv
AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $206.00 price target on the stock.
Low
Report
AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $206.00 price target on the stock.
11/22
07:15 am
abbv
Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast (2025-2030) by Linker, Condition, End Use and Region - Industry Set to Experience 11.8% CAGR Over the Forecast Period [Yahoo! Finance]
Low
Report
Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast (2025-2030) by Linker, Condition, End Use and Region - Industry Set to Experience 11.8% CAGR Over the Forecast Period [Yahoo! Finance]
11/21
06:28 am
abbv
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy [Yahoo! Finance]
Low
Report
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy [Yahoo! Finance]
11/20
11:19 am
abbv
Specialty Pharmaceuticals Research Report: Increased Reimbursement Through Medical and Pharmacy Benefits Driving the Market, Reaching $965 Billion by 2030 [Yahoo! Finance]
Low
Report
Specialty Pharmaceuticals Research Report: Increased Reimbursement Through Medical and Pharmacy Benefits Driving the Market, Reaching $965 Billion by 2030 [Yahoo! Finance]
11/20
10:12 am
abbv
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? [Yahoo! Finance]
Low
Report
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? [Yahoo! Finance]
11/19
05:42 pm
abbv
Biologics CDMO Market to Grow by USD 10.63 Billion (2024-2028), Driven by Cost-Efficient Resources in Emerging Markets, with AI Impacting Market Trends - Technavio [Yahoo! Finance]
Low
Report
Biologics CDMO Market to Grow by USD 10.63 Billion (2024-2028), Driven by Cost-Efficient Resources in Emerging Markets, with AI Impacting Market Trends - Technavio [Yahoo! Finance]
11/19
10:07 am
abbv
Where Will AbbVie Be in 5 Years? [Yahoo! Finance]
Low
Report
Where Will AbbVie Be in 5 Years? [Yahoo! Finance]
11/19
09:40 am
abbv
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Wells Fargo & Company to $195.00. They now have a "buy" rating on the stock.
Low
Report
AbbVie Inc. (NYSE: ABBV) had its price target raised by analysts at Wells Fargo & Company to $195.00. They now have a "buy" rating on the stock.
11/19
07:06 am
abbv
Hormonal Contraceptive Market Projected to Reach 26.7 Billion by 2032 Growing at 4.4% CAGR | Introspective Market Research [Yahoo! Finance]
Low
Report
Hormonal Contraceptive Market Projected to Reach 26.7 Billion by 2032 Growing at 4.4% CAGR | Introspective Market Research [Yahoo! Finance]
11/18
12:11 pm
abbv
Aldeyra announces FDA acceptance of resubmitted reproxalap application [Seeking Alpha]
Low
Report
Aldeyra announces FDA acceptance of resubmitted reproxalap application [Seeking Alpha]
11/18
11:38 am
abbv
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe [Yahoo! Finance]
Low
Report
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe [Yahoo! Finance]
11/18
09:00 am
abbv
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
Low
Report
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
11/18
07:24 am
abbv
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement [Yahoo! Finance]
Low
Report
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement [Yahoo! Finance]
11/18
01:04 am
abbv
Yahoo Finance [Yahoo! Finance]
Low
Report
Yahoo Finance [Yahoo! Finance]
11/18
01:00 am
abbv
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
Low
Report
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
11/15
05:21 pm
abbv
Biosimilars Market to grow by USD 54.35 billion (2024-2028), cost advantage over biologics to drive revenue, Report with the AI impact on market trends - Technavio [Yahoo! Finance]
Low
Report
Biosimilars Market to grow by USD 54.35 billion (2024-2028), cost advantage over biologics to drive revenue, Report with the AI impact on market trends - Technavio [Yahoo! Finance]
11/15
11:54 am
abbv
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? [Yahoo! Finance]
Low
Report
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? [Yahoo! Finance]
11/15
08:04 am
abbv
AbbVie Inc. (NYSE: ABBV) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $205.00 price target on the stock.
Low
Report
AbbVie Inc. (NYSE: ABBV) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $205.00 price target on the stock.
11/14
08:15 am
abbv
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
Low
Report
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
11/13
10:08 am
abbv
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at JPMorgan Chase & Co. from $210.00 to $200.00. They now have an "overweight" rating on the stock.
Low
Report
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at JPMorgan Chase & Co. from $210.00 to $200.00. They now have an "overweight" rating on the stock.
11/12
02:30 pm
abbv
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Citigroup Inc. from $226.00 to $215.00. They now have a "buy" rating on the stock.
Low
Report
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Citigroup Inc. from $226.00 to $215.00. They now have a "buy" rating on the stock.
11/12
12:52 pm
abbv
Glaucoma Therapeutics Market Analysis by Size, Share, and Growth | Market Value 8.02 Billion by 2031 at 3.2% CAGR [Yahoo! Finance]
Low
Report
Glaucoma Therapeutics Market Analysis by Size, Share, and Growth | Market Value 8.02 Billion by 2031 at 3.2% CAGR [Yahoo! Finance]
11/12
12:36 pm
abbv
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at BMO Capital Markets from $228.00 to $208.00. They now have an "outperform" rating on the stock.
Low
Report
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at BMO Capital Markets from $228.00 to $208.00. They now have an "outperform" rating on the stock.
11/12
11:25 am
abbv
Botulinum Toxin Market Analysis by Size, Share, and Growth | Market Value 19.03 Billion by 2031 at 12.6% CAGR [Yahoo! Finance]
Low
Report
Botulinum Toxin Market Analysis by Size, Share, and Growth | Market Value 19.03 Billion by 2031 at 12.6% CAGR [Yahoo! Finance]
11/12
08:33 am
abbv
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Morgan Stanley from $231.00 to $224.00. They now have an "overweight" rating on the stock.
Low
Report
AbbVie Inc. (NYSE: ABBV) had its price target lowered by analysts at Morgan Stanley from $231.00 to $224.00. They now have an "overweight" rating on the stock.